摘要
肝细胞癌属于多血管实体瘤,其发生发展过程与肿瘤血管生成密切相关。肝癌血管生成是一个涉及多种调节因子的复杂过程,受血管生成促进因子及抑制因子的平衡所控制。近年来发现肝癌还存在血管生成拟态(VM)。因此,通过阻断血管生成促进因子的作用、增强血管生成抑制因子的活性,或通过抑制和干扰VM可以达到治疗肿瘤的目的。目前已有10余种分子靶向药物被批准用于临床原发性肝癌的治疗,如索拉非尼、舒尼替尼、贝伐单抗和重组人血管内皮抑素等。本文对肝癌血管生成分子机制和相关分子靶向药物的研究进展进行综述。
Hepatocellular carcinoma（HCC） is a kind of typical hypervascular tumor,whose pathogenetic progression is closely related to tumor angiogenesis.HCC angiogenesis is a complicated process involving a lot of regulatory factors and controlled by the balance between angiogenic stimulators and inhibitors.In recent years,it was also found vasculogenic mimicry（VM） was present in HCC.Therefore,HCC can be treated not only by blocking angiogenic stimulators,enhancing angiogenic inhibitors,but also by inhibiting or interfering with the VM.At present,more than 10 kinds of molecular targeted agents have been approved for clinical treatment of HCC,such as sorafenib,sunitinib,bevacizumab,recombinant human endostatin（Endostar）,and so on.This article reviews the molecular mechanism of angiogenesis and molecular targeted drugs on anti-angiogenesis in HCC.
出处
《国际药学研究杂志》
CAS
2012年第6期469-473,共5页
Journal of International Pharmaceutical Research
基金
四川省教育厅重点项目(11ZA149)
关键词
癌
肝细胞
血管生成
分子靶向药物
carcinoma
hepatocellular
angiogenesis
molecular targeted drugs
